News

In February 2025, ‘cutting edge’ results of IBD research have been presented at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO 2025) in Berlin. In this whitepaper, we discuss the most advanced phase 3 compounds with novel mode of action, which are the TL1A-inhibitors RO7790121 and tulisokibart and the microRNA-124 enhancer obefazimod. In addition, we discuss the early phase product olamkicept, a first-in-class selective IL-6 soluble receptor (sIL-6R) antagonist, which achieved clinical response and clinical remission in a remarkable percentage of IBD patients in an open-label phase 2 induction trial.

The Charité Research Organisation GmbH has long-standing experience in the conduction of early phase projects for new medicines to treat IBD.

We want to share our expertise in this Whitepaper.

Author and Contact:
Claudia Werner, MD, PhD
Charité Research Organisation GmbH
Charitéplatz 1, 10117 Berlin
claudia.werner@charite-research.org